Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer

Resistance to docetaxel is a major clinical problem in advanced prostate cancer. The overexpression of AXL receptor tyrosine kinase (AXL) has been correlated with chemotherapeutic drug resistance. However, the role of AXL expression in docetaxel resistance in prostate cancer is yet unclear. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jian-Zhong, Wang, Zeng-Jun, De, Wei, Zheng, Ming, Xu, Wei-Zhang, Wu, Hong-Fei, Armstrong, Alex, Zhu, Jia-Geng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522277/
https://www.ncbi.nlm.nih.gov/pubmed/28455956
http://dx.doi.org/10.18632/oncotarget.17026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522277/
https://www.ncbi.nlm.nih.gov/pubmed/28455956
http://dx.doi.org/10.18632/oncotarget.17026

Ejemplares similares